Page 20 - Phissons Ethics Dilemma Teaching Guide
P. 20
SWOT
SWOT Analysis
Do Nothing
Phissons are in a position of strength they have invested £250 million
and are weeks away from the launch of proxydychromil which has
received approval in both the UK and US for sale.
Furthermore it is a drug that treats both primary forms of asthma.
